Can IBM’s Watson Help Cancer Patients?

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a joint effort from the American Cancer Society and IBM that aims to use the cognitive power of Watson to help cancer patients deal with their disease.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a joint effort from the American Cancer Society and IBM that aims to use the cognitive power of Watson to offer cancer patients and survivors personalized guidance for their disease.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Second Primary Cancer Risk is Similar in Adjuvant Cemiplimab Vs Placebo in Skin Cancer Subtype

Jax DiEugenio
October 18th 2025
Article

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

Adjuvant Nivolumab Improves Long-Term RFS vs Ipilimumab in Resected Melanoma

Kyle Doherty
October 18th 2025
Article

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Russ Conroy
October 18th 2025
Article

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

BNT111 Plus Cemiplimab Yields Positive Efficacy in PD-(L)1-Relapsed/Refractory Melanoma

Caroline Seymour
October 18th 2025
Article

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.